Analyst Thibault Boutherin from Morgan Stanley maintained a Hold rating on Galderma Group AG and keeping the price target at CHF135.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thibault Boutherin’s rating is based on Galderma Group AG’s recent performance and future prospects. The company demonstrated a strong third-quarter performance, with a notable increase in sales driven by its injectable aesthetics and Nemluvio products. The successful launch of new products and market share gains in both the US and international markets contributed to this growth.
Despite these positive developments, Boutherin’s Hold rating suggests a cautious approach, possibly due to the overall market softness and the need for continued investment in growth initiatives. While the company has upgraded its FY25 guidance, indicating confidence in its future performance, the Hold rating reflects a balanced view, considering both the potential for growth and the challenges that may lie ahead.